Compare Sana Biotechnology Inc (SANA) vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value (VIST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value — how do they compare? Sana Biotechnology Inc trades at $2.85 (market cap $836.71M), while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value trades at $66.76 (market cap $7.43B). The key difference: Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value is far larger — about 8.9× Sana Biotechnology Inc's market cap, and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value for 0 Days on average.
| SANA | VIST | |
|---|---|---|
Market Cap | $836.71M | $7.43B |
Volume | 4,507,444 | 875,552 |
Sector | Health | Energy |
52-Week High | $5.92 | $79.25 |
52-Week Low | $2.68 | $35.02 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $749.96M | $10.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value
Vista Energy is an independent oil and gas company focused on exploration, development, and production in Latin America. Its operations are centered on the Vaca Muerta formation in Argentina.
Read more on VIST →
